Compare ICCC & ABVC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ICCC | ABVC |
|---|---|---|
| Founded | 1982 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 55.5M | 58.6M |
| IPO Year | 1987 | N/A |
| Metric | ICCC | ABVC |
|---|---|---|
| Price | $6.02 | $2.27 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 15.0K | ★ 72.3K |
| Earning Date | 11-13-2025 | 11-03-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.26 | N/A |
| Revenue | ★ $27,769,304.00 | $797,916.00 |
| Revenue This Year | N/A | $735.18 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $23.12 | ★ N/A |
| Revenue Growth | 16.49 | ★ 56.52 |
| 52 Week Low | $4.28 | $0.40 |
| 52 Week High | $7.60 | $5.48 |
| Indicator | ICCC | ABVC |
|---|---|---|
| Relative Strength Index (RSI) | 59.31 | 38.94 |
| Support Level | $4.72 | $1.97 |
| Resistance Level | $5.36 | $2.30 |
| Average True Range (ATR) | 0.32 | 0.16 |
| MACD | 0.11 | -0.01 |
| Stochastic Oscillator | 89.05 | 31.85 |
ImmuCell Corp is engaged in the healthcare sector. The company operates in the development, acquisition, manufacture, and sale of products that improve the health and productivity of cows for the dairy and beef industries. The company operates in two business segment. The Scours segment is dedicated to manufacturing and selling First Defense, a product used to prevent scours in newborn calves, which is regulated by the United States Department of Agriculture (USDA). The Mastitis segment is focused on developing and commercializing Re-Tain, a product to treat subclinical mastitis in lactating dairy cows, which is regulated by the United States Food and Drug Administration (FDA). The company generates the majority of its revenue from the Scours segment.
ABVC BioPharma Inc is a clinical-stage biopharmaceuticals company with an active pipeline of six drugs and one medical device (ABV-1701/Vitargus) under development. Its drug products focus on utilizing its licensed technology to conduct proof-of-concept trials through Phase II of the clinical development process. The firm specializes in botanically based solutions that deliver high efficacy with low toxicity for improved health outcomes.